

Cerecin bolsters pipeline with a strategic acquisition from Boston Scientific

Cerecin acquires an intravenous ketogenic drug named CER-081 designed to target metabolic deficits in neurological conditions.

Ahead of major financial milestones in 2024, Cerecin is focused on portfolio growth to maintain leadership in neurometabolism.

Denver, Colorado, and Singapore – Jan 2024 - Cerecin Inc., a clinical-stage biotechnology company and leader in the development of drugs that address metabolic targets in neurological diseases, announced a deal with Boston Scientific for an intravenous ketogenic compound. The new candidate has been named CER-081. In the transaction, Cerecin acquired a comprehensive package of data for CER-081 that will speed the development of the drug. The deal includes the granting of an option to license to Boston Scientific for the global commercial rights to CER-081.

Numerous neurological diseases have a underlying metabolic or mitochondrial deficit that is either directly causes, or significantly contributes, to the pathophysiology of the condition. Cerecin is focused on developing drugs that address these metabolic targets and is one of the pioneering companies in this field. With this acquisition from Boston Scientific, Cerecin now has five programs and three products in its neurometabolic pipeline. Cerecin's lead candidate is CER-0001, tricaprillin. CER-0001 is a proprietary oral formulation of a structured lipid that acts as a pro-drug for ketone bodies. In conditions where cerebral metabolism is deficient, β -hydroxybutyrate is utilised by the mitochondria to enhance ATP generation, reducing reactive oxygen species, decrease neuroinflammation and ultimately lowering the metabolic burden. CER-0001 is currently entering Phase 3 for mild-moderate Alzheimer's disease, and in the planning stage for Phase 2/3 in migraine and infantile spasms.

The acquisition of CER-081 is a strategic alignment with Cerecin's portfolio expansion strategy, providing synergies that will enhance our capabilities in addressing acute neurological conditions. The direct administration of ketone bodies is closely synergistic with Cerecin's area of domain expertise in ketone metabolism. The intravenous administration of CER-081 allows targeting of a different set of therapeutic indications in which acute treatment, immediacy of effect and non-oral administration are preferable.

Boston Scientific is a leading healthcare company dedicated to transforming lives through innovative medical solutions. Boston Scientific is a multinational leader in the development and commercialisation of medical devices in a broad range of specialities including neuromodulation, neurovascular intervention and critical care. The CER-081 program was acquired by Boston Scientific through the acquisition of BTG International in 2019. BTG is now a wholly owned subsidiary of Boston Scientific.

Chief Scientific Officer, Dr Sam Henderson, commented, "We are excited by the addition of this highly synergistic asset to our pipeline. Cerecin is at the forefront of development of drugs that enhance ketone metabolism. CER-081 will allow us to develop solutions for a broader set of patients." President and CEO, Dr Charles Stacey, added, "We have been focused on maintaining our

leadership in the field of neurometabolism. Innovation and interest in neurology is at an all-time high and the recent success of GLP-1 agonists has highlighted the importance of metabolism in a wide range of diseases. Completion of this transaction at the beginning of 2024 is a great start to a year that will be defining for Cerecin as we approach a series of significant financial milestones.”

About Cerecin:

Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY) and Wilmar International Limited (SGX: F34), as well as a syndicate of leading institutional investors. By bringing together the deep expertise of its leadership team, Cerecin is becoming a global leader in bioenergetics and neurometabolism.

Forward looking statements:

This press release contains “forward-looking statements” under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company’s business, projects, drug development programs and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company’s projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward- looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

For more information visit www.cerecin.com, follow us on LinkedIn

Contact: pr@cerecin.com ©2024 Cerecin